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therapeutic modulators in PAR-driven
inflammatory diseases
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Abstract
Inflammatory diseases have become increasingly prevalent with industrialization. To address this, numerous anti-
inflammatory agents and molecular targets have been considered in clinical trials. Among molecular targets,
protease-activated receptors (PARs) are abundantly recognized for their roles in the development of chronic
inflammatory diseases. In particular, several inflammatory effects are directly mediated by the sensing of proteolytic
activity by PARs.
PARs belong to the seven transmembrane domain G protein-coupled receptor family, but are unique in their lack
of physiologically soluble ligands. In contrast with classical receptors, PARs are activated by N-terminal proteolytic
cleavage. Upon removal of specific N-terminal peptides, the resulting N-termini serve as tethered activation ligands
that interact with the extracellular loop 2 domain and initiate receptor signaling. In the classical pathway, activated
receptors mediate signaling by recruiting G proteins. However, activation of PARs alternatively lead to the
transactivation of and signaling through receptors such as co-localized PARs, ion channels, and toll-like receptors.
In this review we consider PARs and their modulators as potential therapeutic agents, and summarize the current
understanding of PAR functions from clinical and in vitro studies of PAR-related inflammation.
Introduction
The four mammalian members of the protease-activated
receptor (PAR) family PAR1, PAR2, PAR3, and PAR4 are
encoded by the genes F2R [1], F2RL1 [2], F2RL2 [3], and
F2RL3 [4], respectively. Human PAR1 was discovered in
1991 as a key thrombin receptor on platelets [5, 6]. Al-
though human and mouse PAR2 genes are homologous
to PAR1 genes, PAR2 is not responsive to thrombin [2,
7, 8]. Unexpected responses of platelets to thrombin in
PAR1 knockout mice lead to the discovery of the throm-
bin receptors PAR3 and PAR4 [4, 9, 10]. PAR regulation
varies between species and tissues, with differing expres-
sion levels, protease cleaving activities, dimerization with
other receptors, compartimentalization, trafficking,
posttranslational modifications, and co-localization with
co-receptors, as shown in Fig. 1.
Studies of PAR activation under physiological condi-
tions are crucial for the understanding of the patho-
physiological roles of PARs, such as those in
inflammatory disorders.
Cleavage and activation of PARs and signal
transduction
PARs are specifically cleaved and irreversibly activated
by various endogenous proteases, and by exogenous pro-
teases from bacteria, plants, fungi, and insects. Proteases,
soluble or cell membrane associated (bound to
co-receptors or specific membrane compartments),
cleave specific N-terminal peptides of PARs, resulting in
exposure of new N-terminal peptides that serve as teth-
ered activation ligands, which bind a conserved region
on extracellular loop 2 (ECL2) [5, 11]. This interaction
initiates conformational changes and alters affinity for
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intracellular G proteins [12]. Various N-terminal cleav-
age sites have been described, and these have various ac-
tive conformations with specific G protein preferences.
Multiple cleavage site-specific cellular responses are gen-
erally referred to as biased signaling, and the ensuing
models describe how distinct proteases with distinct
cleavage sites induce protease-specific responses via the
same PAR [13, 14].
In contrast with PAR-activating proteases, other prote-
ases cleave PARs at cleavage sites that are not related to
signaling. Under these conditions, shedding of the PAR1
terminus, which removes the thrombin activation site,
was first recognized as a mechanism for rendering plate-
lets irresponsive to thrombin [15]. These truncated PARs
can no longer be proteolyticaly activated, but remain ac-
tivated by ligands from adjacent PARs [16]. Alternatively,
truncated PARs bind soluble peptides with affinity for
ECL2 by mimicking the tethered ligand. Both mecha-
nisms result in receptor activation [17, 18]. Multiple
ECL2-binding agonist peptides have been described and
shown to induce signaling from truncated and uncleaved
PARs (see agonist peptides in Tables 5, 6, 7).
PAR activation by proteolytical cleavage
PAR-cleaving proteases are a focus of many current
studies. Whereas some PAR-cleaving proteases produce
N-terminal components with regulatory roles, others
render the receptors irresponsive to further protease ex-
posure as shown in Fig. 2 and summarized in Tables 1,
2, 3 and 4. Important proteases are discussed below.
Mammalian proteases
Serine proteases Thrombin, the key protease of coagu-
lation, is generated by proteolytic cleavage of zymogen
prothrombin. Although thrombin production predomin-
antly occurs on platelets and subendothelial vascular
walls, extravascular thrombin has been detected in syn-
ovial fluid [19] and around tumors [20]. Thrombin has
long been known to activate platelets, and the discovery
of PAR1 initiated research into the underlying molecular
mechanisms. PAR1 contains a hirudin-like domain,
which has a high affinity thrombin binding site and re-
cruits thrombin via exosite I. This interaction enables
thrombin to specifically and efficiently activate PAR1 [6].
Similarly, PAR3 contains a hirudin-like thrombin re-
cruitment site, which results in cleavage [9, 21]. In other
studies, mouse PAR3 maintained thrombin recruitment
activity but lost its receptor function, as discussed above
[22–24]. Thrombin also cleaves and activates PAR4,
which, in contrast with PAR1, lacks a hirudin-like do-
main. Thus, higher concentrations of thrombin activate
PAR4 and initiate intracellular signaling [10]. PAR2 is
considered the only PAR that resists cleavage or
Fig. 1 Mechanisms of PAR activation. PAR activation is regulated by a direct proteolytic cleavage at the N-terminus, b homo- or
heterodimerization with other PARs and transactivation through the cleaved tethered ligand, c compartmentalization on the cell surface, d
degradation or recycling by endosomal trafficking, e posttranslational modifications such as glycosylation, phosphorylation, and ubiquitination,
and f co-localization with other receptors and cofactors
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activation by thrombin [4, 25], although emerging evi-
dence suggests that at very high concentrations (100–
500 nM), thrombin may directly cleave and activate
PAR2 [26, 27].
In contrast with thrombin, the anticoagulant prote-
ase activated protein C (aPC) binds to the
co-receptor endothelial protein C receptor (EPCR) to
promote the cleavage and activation of co-localized
PAR1 [28, 29] and induce anti-apoptotic and protect-
ive effects on endothelial barrier permeability [29–33].
Compartmentalization of PAR1 and co-localization
with EPCR in calveolae is crucial for efficient cleavage
by aPC [13]. Moreover, aPC cleaves PAR3 in humans
and mice [21, 34, 35] and acts as a PAR3 shedding prote-
ase that prevents thrombin-induced barrier disruption
[21]. However, the dependency of aPC cleavage of PAR3
on EPCR remains controversial [21, 35]. Similar to aPC,
coagulation factor Xa binds EPCR and mediates proteo-
lytic activation of PAR1 and PAR3 [21, 28, 36–39]. In
addition, EPCR-bound factor Xa reportedly cleaves PAR2
and initiates inflammatory signaling [40]. PAR2 was also
shown to be activated by tissue factor (TF)-bound coagu-
lation factor VIIa [40–42]. Yet recent studies suggest that
the TF-VIIa complex does not directly activate PAR2, and
rather activates matriptase, which cleaves and activates
PAR2 [42–44]. Anti-inflammatory signaling was also pre-
viously related to PAR1 cleavage by EPCR-bound VIIa [45,
46]. Taken together, these studies indicate that TF-Xa–
VIIa complexes activate PAR1 and PAR2 [47].
Trypsins are PAR-activating proteases with roles as major
digestive enzymes in the duodenum [48]. Trypsin is also se-
creted by epithelial cells, nervous system cells [49], and
tumor cells [50, 51]. Trypsins may also be involved in cell
growth and coagulation, as suggested by secretion from
human vascular endothelial cells [52]. Trypsin cleaves
human PAR1 and PAR4 at putative protease cleavage
sites, and thereby prevents thrombin signaling in
endothelial cells and platelets [4, 53]. Trypsin is the
major PAR2 cleaving protease that initiates inflamma-
tory signaling [2, 7].
Fig. 2 Proteolytic PAR cleavage. a N-terminal sequences of human PARs (PAR1–4) containing potential cleavage sites. b Proteolytic cleavage of
PARs by soluble exogenous proteases exposes new N-terminal sequences that serve as tethered ligands for G protein dependent activation of
receptors. Alternatively, proteolytic cleavage at other sites destroys the function of the receptor to prevent intracellular signal transduction
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Tryptase is the main protease of mast cells, and activates
PAR2 by proteolytic cleavage to induce calcium signaling
and proliferation [54–57]. The source tissue of tryptase re-
portedly plays an important role in the cleavage and induc-
tion of tryptase-activated PAR signaling, reflecting
differences in posttranslational modifications, such as gly-
cosylation and sialic acid modifications [54, 58]. Tryptase
induces calcium signaling via PAR1 when PAR2 is
co-expressed, but cannot activate human platelets, suggest-
ing that tryptase does not directly cleave PAR1 [54–57].
Chymase is a mast cell serine protease that also cleaves
PAR1 in human keratinocytes and fibroblasts, and thus pre-
vents thrombin sensitivity [59]. Moreover, the epithelial
serine protease matriptase cleaves and initiates inflamma-
tory responses in human and mouse keratinocytes and in
Xenopus oocytes overexpressing human PAR2 [44, 60–63].
PARs have been identified as substrates of kallikreins,
which are serine proteases that have been related to
various inflammatory and tumorigenic processes [64].
Kallikrein-4 increases intracellular calcium levels via
PAR1 and PAR2, but activates PAR1 most efficiently
[65]. Kallikrein-14 induces calcium signaling via PAR1,
PAR2, and PAR4, but can also shed PAR1 to prevent sig-
naling. Rat platelets are activated by kallikrein-14 via the
proteolytic cleavage of PAR4, but are not activated by
kallikrein-5 and kallikrein-6 [66]. Instead, neurotoxic ef-
fects of kallikrein-6 were inhibited by blocking PAR1
and PAR2, indicating a direct proteolytic role in PAR ac-
tivation [67].
Neutrophils are mobilized to sites of inflammation and
infection, where they modulate inflammatory signaling, in
part by secreting PAR-cleaving proteases. The neutrophil
serine protease cathepsin G prevents thrombin-induced
effects by cleaving PAR1 into non-functional parts [68,
69]. In contrast, cathepsin G reportedly induced chemo-
attractant signaling via PAR1, further supporting the role
Table 1 PAR1 cleaving proteases
Protease Major cleavage site Additional cleavage sites
Mammalian proteases Thrombin R41S42
aPC R46N47 R41S42
FVIIa unknown
FXa R41S42
Trypsin R41S42
Chymase unknown
MMP-1 D39P40, L44L45, F87I88 N47P48, R70L71,K82Q83
MMP-2 L38D39
MMP-3,-8,-9 R41S42
MMP-12 unknown
MMP-13 S42F43 L38T39, mouse
Cathepsin G R41S42, F55W56, Y69R70
Neutrophil elastase A36T37, V72S73, A86F87
Proteinase-3 A36T37, P48N49, V72S73, A92S93
Plasmin K32A33, R41S42, R70 L71, K76 S77, K82 Q83
Kallikrein-4,-5,-6 unknown
Kallikrein-14 R46N47
Granzyme A,B, K unknown
Calpain-1 K32A33, S76K77
Non-mammalian proteases PA-BJ R41S42, R46N47
Thrombocytin R41S42, R46N47
DerP1 unknown
Gingipain R R41S42
SpeB L44L45
LepA unknown
S.pneumoniae proteases unknown
Thermolysin F43L44, L44L45
penC R41S42
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of cathepsin G in PAR1 activation [70]. Another unex-
pected observation of cathepsin G was that cleavage sites
differ between recombinant and native human PAR2 [26,
71, 72]. These discrepancies may reflect the influence of
cell types and posttranslational modifications on PAR
cleavage. Studies in mice and humans show that platelet
activation by cathepsin G is dependent on PAR3 and
PAR4 [71, 73, 74]. Cathepsin G also cleaves and activates
PAR4 on endothelial cells [75]. The neutrophil proteases
elastase and proteinase-3 cleave recombinant PAR1 and
PAR2 at various sites [26, 72]. Recently, rat elastase was
shown to cleave and activate PAR1, although sequences of
rat and human PAR1 have low homology [76]. In contra-
diction with neutrophil proteases that prevent PAR signal-
ing at sites of inflammation, monocytes secret the
protease cathepsin S, which initiates inflammatory
Table 2 PAR2 cleaving proteases
Protease Major cleavage site Additional cleavage sites
Mammalian proteases Thrombin R36S37
aPC unknown
FXa R36S37
Trypsin R36S37 K34G35, K51G52, K72L73
Tryptase R36S37
Chymase G35R36 L38I39, mouse
Matriptase R36S37
Cathepsin G F65S66 F59S60, F64S65
Cathepsin S G40K41 E56P57, mouse
Neutrophil elastase A66S67, S67V68 V42D43,V48T49,V53T54,V58T59,T74T75,V76F77
Proteinase-3 D62E63 V48T49,V55E56,T57V58 V61D62,K72L73,T74T75,T75V76,V76F77
Plasmin R36S37 K34G35
Testisin unknown
Kallikrein-4, unknown
Kallikrein-5,-6,-14 R36S37
Calpain-2 unknown
Non-mammalian proteases Der-P1,-P2,-P3,-P9 unknown
Cockroach E1-E3 R36S37
Gingipain R unknown
LepA unknown
EPa S37L38 S38L39, rat
S.pneumoniae proteases unknown
Thermolysin unknown
Serralysin unknown
P.acnes proteases unknown
aPA unknown
Bromelain unknown
Ficin unknown
Papain unknown
penC R36S37
Table 3 PAR3 cleaving proteases
Protease Major cleavage site Additional cleavage sites
Mammalian proteases Thrombin K38T39 mouse PAR3 at K37S38
aPC R41G42
FXa R41G42
Trypsin unknown
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signaling by cleaving PAR2 [72, 77, 78]. Low concentra-
tions of the fibrinolytic protease plasmin prevent platelet
activation by cleaving PAR1, whereas high concentrations
of plasmin lead to the cleavage and activation of PAR1
[79]. Plasmin also cleaves PAR2 and prevents subsequent
activation by trypsin [26, 80].
The serine proteases granzyme A and granzyme B in-
duce intracellular signaling pathways that lead to neur-
onal death via PAR1 [81, 82]. Recently, granzyme K was
also shown to activate PAR1 and promote inflammatory
endothelial signaling [83, 84]. Few studies show activa-
tion of PAR1 by proteases of the granzyme family, and
the details of this interaction remain poorly
characterized.
Cysteine proteases Calpain-1 is a calcium-dependent
cysteine protease that has been associated with inflam-
matory disorders, and initiates calcium signaling path-
ways by activating PAR1 [26]. At very high
concentrations, calpain-2 was also shown to cleave
PAR2, and the authors suggested that this cleavage event
inactivated PAR2 [26]. Recently, calpain-1 was shown to
be induced by thrombin-activated PAR1, and subse-
quently regulated the internalization of PAR1 [85].
Metalloproteases Matrix metalloproteases (MMPs) are
known to be involved in various inflammatory- and
cancer-related conditions. MMP-1 cleaves human PAR1
and initiates platelet activation [86–89]. MMP-1 also
regulates cancer cell activities depending on PAR1 avail-
ability [90]. Similarly, MMP-2 cleaves human PAR1 and
enhances platelet activation [91], and MMP-3, MMP-8,
and MMP-9 were shown to induce platelet activation via
PAR1 [92]. Whether these three MMPs cleave PAR2 is
not clear, although PAR2 activation by trypsin induced
secretion of MMP-9 in human airways, suggesting that
MMP-9 is a PAR2-activating protease [93]. In mice,
PAR1 expression was regulated by MMP-12, and acti-
vated PAR1 increased MMP-12 secretion [94, 95]. A
similar feedback loop involving MMP-12 and PAR2 has
been reported in mice [96]. Moreover, MMP-13 was
shown to activate PAR1 and induce intracellular signal-
ing [87], and thrombin-induced activation of PAR1 and
PAR3 was associated with increased levels of MMP-13
in human chondrocytes [24].
In addition to coagulation and inflammation, PAR acti-
vation may play roles in human germ cells, where the
serine protease testisin activates PAR2 and induces cal-
cium signaling and ERK1/2 activation. This interaction
may play roles in the regulation of ovarian and testicular
cancer, as suggested previously [97, 98].
Non-mammalian proteases
Exogenous proteases from various species that modulate
PAR activation are disscues in the following section and
are summarized in Fig. 3.
Bacterial proteases Endogenous mammalian proteases
are not the only regulators of PAR activation. Indeed,
both pathogenic and commensal bacteria secret various
proteases that cleave PARs and act as inflammatory
modulators [99]. In this section, we describe bacterial
proteases that either activate PARs, and thus allow bac-
teria to penetrate host barriers, or inactivate PARs to
prevent inflammatory signaling by the host.
The human pathogen Pseudomonas aeruginosa secrets
two PAR-cleaving proteases with contrasting effects. The
exoprotease LepA cleaves and activates PAR1, PAR2,
and PAR4, and subsequently induces nuclear factor
kappa B (NFκB) promoter activity [100], whereas
Table 4 PAR4 cleaving proteases
Protease Major cleavage site Additional cleavage sites
Mammalian proteases Thrombin R47G48
Trypsin R47G48
Cathepsin G R47G48
Kallikrein-14 unknown
Non-mammalian proteases PA-BJ R47G48
Thrombocytin R47G48
Der-P3 unknown
Gingipain R R47G48
LepA unknown
S.pneumoniae proteases unknown
Bromelain unknown
Ficin unknown
Papain unknown
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cleavage by elastase EPa inactivates PAR2 to prevent in-
flammation in lungs [101].
The streptococcal pyrogenic exotoxin B (SpeB) of
Group A Streptococcus also inactivates PAR1 by cleav-
ing it, and thereby renders human platelets unrespon-
sive to thrombin [102]. In mice, proteases of
Streptococcus pneumoniae cleaved PAR2 and facili-
tated the spread of the pathogen from the airways
into the blood stream [103]. PAR1 has also been as-
sociated with S. pneumonia-mediated sepsis in mice,
although direct cleavage of PAR1 was not shown
[104, 105]. Pulmonary inflammation from S. pneumo-
niae infections is reduced in PAR4 knockout mice
[106], further supporting this causal link.
Inflammation-associated periodontal diseases are pre-
dominantly induced by the Porphyromonas gingivalis
cysteine protease gingipain R, which activates PAR2
[107, 108]. Subsequently, gingipain R activates PAR1 and
PAR4, and thereby, human platelets [109–111]. This
mechanism may also explain associations between peri-
odontitis and cardiovascular events [112].
In addition, supernatants from Propionibacterium
acnes cultures initiated inflammatory signaling in hu-
man keratinocytes via PAR2 [92]. The virulence of P.
acnes was also reduced in PAR2 knockout mice [113],
further suggesting that PAR2 is involved in bacterial
infections.
Serralysin is a matrix metalloprotease expressed by
Serratia marcescens, and induced inflammation in hu-
man airway cells via PAR2 in vitro [114].
Finally, Bacillus thermoproteolyticus rokko secretes the
metalloprotease thermolysin, which cleaves and inacti-
vates PAR1 to prevent thrombin-induced signaling in rat
astrocytes [115, 116]. The in vitro effects of
PAR2-cleavage by thermolysin, however, vary between
cell lines [116].
Amoeba proteases In acanthamoebic keratitis, PAR2
triggers inflammation following secretion of the plas-
minogen activator (aPA) by Acanthamoeba strains, lead-
ing to induction of IL-8 in human corneal epithelial cells
[117].
Reptile proteases Following snakebites, coagulation dis-
orders in humans and mice occur due to the presence of
venom proteases. In Proatheris superciliaris bites, venom
proteases activate platelets by activating PAR1 and PAR4
[118]. Bothrops atrox and B. jararaca are snake species
of the family viperidae. These snakes secrete the serine
proteases PA-BJ and thrombocytin, which activate hu-
man platelets via PAR1 and PAR4 [119].
Insect proteases Several cysteine and serine proteases
from insects induce inflammation-associated diseases
Fig. 3 Non-mammalian exogenous proteases induce PAR-driven pathological effects. Various proteases are secreted from bacteria, amoebae,
insects, plants, fungi, and snakes, and can cleave PARs and modulate signal transduction, leading to inflammation, thrombosis, or pain
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such as asthma. For example, dust mite allergens contain
the serine proteases DerP2, DerP3, and DerP9 [120] and
the cysteine protease DerP1. DerP1 induces
PAR2-dependent signaling, whereas thrombin-induced
PAR1-signaling is prevented by these proteases in hu-
man epithelial cells [121]. DerP3 was also recently
shown to activate PAR4, and this process was associated
with allergies to dust mites [122].
Similar to proteases from house dust mites, three
serine proteases (E1–E3) from cockroach extracts acti-
vate PAR2 and induce inflammatory signaling in mice
and humans [123–125].
Fungal proteases Pen C is a serine protease from Peni-
cillium citrinum that induces IL-8 in human airway cells
by activating PAR1 and PAR2 [126]. Proteases from As-
pergillus fumigatus have also been shown to prevent
PAR2-dependent inflammation [127]. Moreover, serine
proteases from Alternaria alternate induced calcium sig-
naling in human bronchial cells and induced inflamma-
tion in mice by secreting IL-33 following PAR2
activation [128–130].
Plant proteases Bromelain is a mixture of cysteine pro-
teases that is extracted from pineapple which is used as
a PAR-independent anti-inflammatory agent [131]. Bro-
melain cleaves PAR2 and thereby prevents the associated
inflammatory signaling [132]. In another study, however,
bromelain, ficin, and papain activated PAR2 and PAR4
by proteolytic cleavage, leading to increased intracellular
calcium levels [133]. Thus, further studies are required
to further clarify the modes of action of pineapple
proteases.
Cleavage-independent PAR activation by agonist peptides
Independent of proteolytic cleavage, PARs can be acti-
vated by synthetic soluble ligands corresponding with
cleaved N-terminal sequences, or can be transactivated
by cleavage-generated N-terminal regions of homo- or
heterodimer partners.
Synthetic peptides that mimic the first six amino acids
of tethered N-terminal ligands can act as agonist pep-
tides that activate PARs in the absence of cleavage
events [11, 18, 134]. Specific activation of PARs by a sol-
uble agonist peptide was first shown for human PAR1
with the peptide SFLLRN [6, 18]. However, this peptide
also activated PAR2 [135–137] and therefore various
peptides were tested for specific PAR1 activation. Yet,
PAR1 was the most specifically and efficiently activated
by TFLLRN [138]. In addition to thrombin agonist pep-
tides, other PAR1 agonist peptides have been identified.
In particular, the peptide NPNDKYEPF reproduced the
effects of aPC [28], and PRSFFLRN corresponds with
the N-terminal peptide generated by MMP-1 [86].
SLIGKV corresponds with the trypsin cleaved
N-terminal region of human PAR2. However, the corre-
sponding rat N-terminus SLIGRL is a more specific and
efficient PAR2 agonist in rodents and humans [136,
139], and only the synthetic peptide LIGRLO achieved
this effect more efficiently than SLIGRL in humans
[140]. The roles of ECL-2 in specific PAR activation have
been shown using labeled PAR2 agonist peptides [141,
142]. Because the thrombin generated PAR3 peptide
does not activate the G protein autonomously, no such
agonist peptides have been identified to date [9, 143].
GYPGKF corresponds with the thrombin-cleaved human
PAR4 and has weak activity as an agonist [144]. But re-
placement of the first amino acid glycine (G) with ala-
nine (A) induced PAR4 by 10-fold. This peptide may be
suitable as a platelet activator in humans and mice [145].
Several models of PAR–PAR interactions have been
proposed and extensively studied based on PAR transac-
tivation by agonist peptides [146]. When PAR1 is
blocked on endothelial cells, however, thrombin, and not
the PAR1-specific agonist peptide TFLLRN, induces sig-
naling, reportedly by facilitating the heterodimerization
of PAR1 and PAR2 [147]. Thrombin activation of the
PAR1–PAR2 heterodimer leads to constitutive internal-
ization and activation of β-arrestin by the PAR1 C-tail
[146]. Accordingly, the required co-localization of PAR1
and PAR2 was shown in a human overexpression sys-
tem, in mice studies of sepsis, and in PAR1–PAR2-dri-
ven cancer growth in a xenograft mouse model [148,
149]. In other studies, stable heterodimerization of hu-
man PAR1 and PAR4 was shown in platelet cells, and
thrombin accelerated platelet activation under these
conditions [150, 151]. Similar studies of mouse platelets
showed efficient activation of platelets by thrombin in
the presence of PAR3–PAR4 heterodimers [143]. Con-
sistent with the thrombin-cleaved PAR3 peptide, which
is not self-activating, PAR3 signaling was observed in
the presence of PAR1 or PAR2 [22, 23, 34, 152]. Yet, het-
erodimerization influenced signal transduction and PAR
membrane delivery due to enhanced glycosylation [153].
In addition to activation by heterodimerization, PARs
interact with other receptors, such as ion channels, other
G protein-coupled receptors (GPCRs), receptor tyrosine
kinases (RTKs), receptor serine/threonine kinases
(RSTKs), NOD-like receptors, and TLRs [154]. In par-
ticular, PAR2 initiated inflammatory signaling pathways,
resulting in pain due to transactivation of the ion chan-
nels TRPV1 and TRPV4 in humans and mice [155–159].
Similar inflammatory effects follow transactivation of the
RTKs EGFR and VEGFR by PAR2 and PAR4 [160–163].
Bacterial interactions with PARs suggest important roles
of PARs in infectious disease. In agreement, TLRs
recognize bacteria-derived molecules and contribute to
innate immunity [164, 165]. Moreover, direct
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interactions of PAR2 with TLR3 and TLR4 were neces-
sary for inflammatory responses to LPS in human cell
lines and knockout mice and rats [166–171].
PAR signaling
Activation pathways
PARs belong to a large family of GPCRs and induce
multiple signaling pathways after coupling with heterodi-
meric G proteins. Activation of the Gα-subunit due to
the exchange of a guanine from GDP to GTP results in
dissociation of the Gβγ-dimer and activation of down-
stream pathways [172, 173].
Following proteolytic cleavage or induction of agonist
peptides, the engaged signaling pathways vary between
tissues, cell lines, and the availability of co-receptors for
transactivation. Depending on the ligand, specific
α-subunits are activated, and these regulate subsequent
cellular functions as summarized in Fig. 4. For example,
thrombin-stimulated PAR1 activates the small GTPase
protein RhoA via ERK1/2 kinases, but not via Rac1,
whereas aPC-stimulated PAR1 induces Rac1 via Akt kin-
ase, but not via RhoA [13, 174–176]. Moreover, in ac-
cordance with PAR1 cleavage sites, aPC prevents
thrombin-induced RhoA signaling [16]. However, in
contrast with thrombin-induced RhoA activation on
platelets and endothelial cells, PAR1-agonist peptides
and thrombin activated the inhibitory G protein Gi
which leads to the inhibition of adenylyl cyclase in hu-
man fibroblasts [177, 178]. Other studies indicate that
PAR2 activation is less tissue specific than PAR1 activa-
tion, and trypsin and VIIa cleaved PAR2 and activated
Gαq and Gi, resulting in calcium influx, MAPK activa-
tion, and inflammatory signaling [8, 179].
Signaling by tethered ligands can differ from that gen-
erated by corresponding soluble agonist peptides. For
example, thrombin-cleaved PAR1 activated Gα12/13 and
Gαq and induced Rho and Ca
2+ signaling, whereas the
PAR1-agonist peptide activated only Ga12/13 and down-
stream RhoA-dependent pathways that affected endothe-
lial barrier permeability [180]. Similar observations of
human platelets suggested that platelet activation
followed coupling of thrombin-activated PAR1 with mul-
tiple heterotrimeric G protein subtypes, including Gα12/
13 and Gαq [181–183]. Moreover, trypsin and the
PAR2-agonist peptide induced ERK1/2 signaling and in-
flammation by activating PAR2 [29, 180, 184–186].
β-arrestins also play major roles in PAR-induced signal-
ing independently of G protein activation. For instance,
aPC-activated PAR1 induces cytoprotective effects by
recruiting β-arrestin in endothelial cells. Thus, aPC
cleavage fails to protect β-arrestin deficient cells from
the effects of thrombin [187, 188]. In addition, multiple
studies show that activated PAR2 co-localizes with
β-arrestin-1 and arrestin-2 and induces ERK1/2 signaling
[77, 189–191].
Desensitization and termination
PAR activation is regulated by internalization and pro-
teolytic desensitization, which limits the duration of sig-
naling. For instance, PAR1 is constitutively internalized
and recycled or agonist-induced internalized and de-
graded as described in [192, 193] and shown in the
scheme of Fig. 5. As discussed above, some
PAR-cleaving proteases abolish receptor responses by re-
moving (shedding) or destroying the tethered ligands.
For example, PAR1 is inactivated following cleavage by
cathepsin G, and thrombin activation is hence pre-
vented, allowing the formation of clotting under inflam-
matory conditions.
Depending upon proteolytic cleavage, PAR1 rapidly
internalizes or accumulates on the cell surface [194, 195].
Activated PAR1 is internalized via clathrin- and
dynamin-dependent mechanisms, and is sorted from early
endosomes to lysosomes for degradation [196–199].
Fig. 4 G protein-coupled signaling induced by PAR activation.
Depending on the tethered ligand, activated PAR couples with G
protein α-subtypes. Gαq activates phospholipase Cβ (PLCβ), which
mobilizes calcium. This further activates MAPKs (ERK1/2) and induces
Ras signaling. Primarily, Gα12/12 and Gaq activate the Rho pathway.
Gαi inhibits the activation of adenylyl cyclase, which leads to
reduced production of cAMP. In contrast, the βγ-subunit functions
as a negative regulator when bound to the α-subunit. After receptor
activation, subunits separate, and the βγ-subunit interacts with other
proteins, thereby activating or inhibiting signaling
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Although the mechanisms that terminate PAR1 sig-
naling are not clearly understood, this process is
known to involve phosphorylation, ubiquitination, and re-
cruitment of β-arrestin [200–204]. In contrast with PAR1,
activated PAR2 is not constitutively internalized [205].
Thus, to prevent persistent signaling upon activation,
PAR2 is phosphorylated and ubiquitinated and then binds
β-arrestin before being internalized and degraded [206–
208]. Under these conditions, the activated and internal-
ized PAR2 is not recycled and instead induces
β-arrestin-dependent endosomal ERK1/2 signaling in the
cytoplasm [189, 191, 209]. Thus, large cytoplasmic stores
of newly generated PAR2 are required for rapid
externalization and activation on cell membranes [210].
Although less is known about how PAR4 signaling is
terminated, recent observations suggest that PAR4 in-
ternalization is independent of β-arrestin and slowly
occurs via clathrin- and dynamin-dependent pathways
[211]. In agreement, human platelets internalized PAR4
much slower than PAR1, and exhibited prolonged PAR4
signaling activity [212]. Moreover, growing evidence indi-
cates that PAR–PAR heterodimerization is important for
internalization, and that the underlying mechanisms in-
clude PAR2-dependent glycosylation of PAR4, thus affect-
ing membrane transport [153]. Upon internalization,
endosomal PAR4 dimerizes with the purinergic receptor
P2Y12 and induces Akt signaling by recruiting β-arrestin
within endosomes [213].
Depending on stimuli, PAR expression patterns
are regulated by complex combinations of cell
surface presentation, endocytosis, vesicle born or
recycled (i.e., re-exocytosed) receptors, and traffick-
ing modes that are linked to posttranslational modi-
fications of PAR.
Role of PARs in inflammation
With the current increases in the prevalence of inflam-
matory diseases, published in in vitro and in vivo studies
of the roles of PARs in inflammation have become more
numerous. These are reviewed below.
Systemic inflammation and inflammatory cells in the
cardiovascular system
PARs are critical for the interplay between clotting pro-
teases of platelets, endothelial cells, and vascular smooth
muscle cells that regulate hemostasis, vascular barrier
function, vascular tone, vascular homeostasis, cell adhe-
sion, and inflammatory responses [150]. The roles of
PARs in these processes vary significantly between spe-
cies. Specifically, whereas functional PAR1 and PAR4 are
expressed in human platelets [214], PAR1, PAR3, and
PAR4 have been found in guinea pig platelets [215].
Whereas mouse and rat platelets lack PAR1, they are ac-
tivated at low concentrations of thrombin, which is re-
cruited by PAR3 onto the surface of platelets and then
efficiently activates PAR4 [4]. Due to interspecies differ-
ences in PAR expression, mouse and rat studies of PARs
are difficult to translate to humans. PARs in endothelial
cells contribute positive regulatory signals for endothelial
adhesion molecules such as vascular cell adhesion
molecule-1 (VCAM-1), intercellular adhesion molecule-1
(ICAM-1), and E-selectin [216, 217], all of which promote
vascular barrier function. As a counterpart of intravascular
cells, PAR4 induces leukocyte migration [75], and PAR2
expressed on macrophages promotes inflammatory modu-
lators such as interleukin-8 (IL-8) [218]. These modes of
signaling all contribute to a complex PAR-mediated inter-
play of endothelial cells that is orchestrated by intravascu-
lar cells and cytokine secretion. In addition, PARs,
Fig. 5 PAR trafficking. Activation-independent constitutive or agonist-induced internalization regulates PAR1 signaling
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particularly PAR1, regulate vascular barrier function, and
hence, extravasation of macromolecules such as comple-
ment proteins and antibodies. In addition,
thrombin-mediated activation of PAR1 increases endothe-
lial barrier permeability by activating mitogen-activated
protein kinases (MAPKs) [219]. Although this effect is re-
versed by activated protein C (aPC)-mediated activation of
PAR1 [28, 174, 175, 220]. Thrombin further promotes
prostaglandin 2 (PGE2) secretion, and consequent endo-
thelial barrier permeability [221]. Similarly, PAR1 activa-
tion increased vascular leakage in a murine model [222].
Inflammatory mediators, such as tumor necrosis factor
alpha (TNFα), were shown to regulate the expression of
endothelial PAR2, and the authors suggested that these
data were indicative of barrier protective effects of PAR2
[223]. Several other studies show that PAR2 activation in-
duces endothelium-dependent relaxation in blood vessels
of mice and in arteries of rats [224–228]. In contrast, dual
activities of PAR2 on blood vessels were reported in a
study of rats [229]. In this line, thrombin-activated PAR1
induced the expression of vascular endothelial growth fac-
tor in smooth muscle cells [230], thus revealing the rela-
tionship between coagulation and vascular growth.
Although the roles of PARs in the development of arterio-
sclerosis are yet to be elucidated, PAR2 and PAR4 were in-
duced in human arteries under inflammatory conditions
[223], suggesting important roles of PARs in vascular
inflammation.
Chronic inflammation of the gastrointestinal tract
In the gut lumen, human and bacterial proteases are
both present at high concentrations. Similar to endothe-
lial barriers, proteases regulate intestinal barrier perme-
ability via PARs, all four of which are expressed by cells
of the gastrointestinal tract [9, 224, 231, 232]. Trypsins
and tryptases are prominent intestinal proteases, sug-
gesting likely involvement of PAR2 as a major receptor of
intestinal inflammation. In accordance, intestinal tight
junctions are disrupted by PAR2-activating proteases,
leading to inflammatory signaling in humans and rats
[139, 206, 233, 234]. Although the roles of PARs in irrit-
able bowel syndrome (IBS) and inflammatory bowel dis-
eases remain unclear, roles of PARs in intestinal barrier
function have been described. Specifically, PAR1 and
PAR2 regulated permeability and chloride secretion,
which are involved in diarrhea and constipation in IBS pa-
tients [234–236]. In addition, activated endosomal PAR2
caused persistent pain in a mouse model of IBS [209].
Inflammatory diseases of the respiratory system
It has long been suggested that PARs are involved in the
pathophysiology of respiratory disorders, reflecting ob-
servations of elevated levels of PAR-activating proteases,
such as thrombin and tryptase, in bronchoalveolar lavage
fluid from patients with pulmonary inflammation [237,
238]. In a sheep asthma model and in asthmatic patients,
tryptase inhibitors reduced inflammation [239, 240], fur-
ther indicating important roles of PAR2 in respiratory
disease. These roles of PARs are also suggested by the
prominence of a variety of non-mammalian
PAR-activating proteases, such as those of house dust
mites and cockroaches [120, 123, 124]. Expression of
PAR1, PAR2, and PAR4 on bronchial epithelial and
smooth muscle cells induced inflammatory signaling in
multiple studies [55, 121, 241–245]. PAR2 is also upreg-
ulated in epithelial cells of patients with asthma and
chronic obstructive pulmonary syndrome (COPD) [246,
247]. Whether PAR2 activation results in bronchocon-
striction or dilatation remains controversial, in part
owing to interspecies differences and tissue dependen-
cies [242, 248, 249]. In humans, however, PAR1-agonist
peptides with thrombin, and a PAR2-agonist peptide
with trypsin and tryptase, induced bronchoconstriction
by inducing Ca2+ signaling in airway smooth muscle
cells [241, 244]. Moreover, the long-term activation of
PAR1 and PAR2 led to pulmonary fibrosis in mice
models [250].
Inflammatory skin diseases
High concentrations of exogenous proteases are present
on the skin of various species, and these may activate
PARs to regulate epidermal permeability and barrier
function [251]. Indeed, epidermal inflammation has been
linked to PAR1 and PAR2 activation in keratinocytes,
which comprise the epidermal barrier with
sub-epidermal skin fibroblasts [179, 252, 253]. Subse-
quent release of IL-8, IL-6, and granulocyte macrophage
colony-stimulating factor (GM-CSF) was also observed
previously [254], potentially involving NFκB activation
[255]. In addition, the inflammatory roles of PAR2 have
been demonstrated in mice models of atopic dermatitis
due to elevated tryptase and PAR2 expression levels
[256, 257]. Similar to studies in mouse models, PAR2
was upregulated in patients with atopic dermatitis, and
PAR2 agonists increased itch, causing irresponsiveness
of sensory nerves to therapy with antihistamines [258].
Rheumatic disease
“Rheumatic disease” is a common term for autoimmune
diseases that affect joints, bones, and muscles. Although
rheumatic disorders are numerous, some of the common
underlying symptoms include chronic joint inflamma-
tion, stiffness, and pain [259]. Currently, PAR2 is the
only PAR that has been associated with the development
of rheumatic diseases [260]. Direct roles of PAR2 in
rheumatic diseases were first indicated in 2003 in a
mouse study by Ferrell et al. [261]. In their study, a
PAR2-agonist peptide induced strong inflammatory
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effects in wt mice, causing joint swelling and synovial
hyperemia, whereas joint swelling was absent in PAR2
deficient mice [261]. Similarly, in patients with rheuma-
toid arthritis, PAR2 is upregulated in inflamed tissues
[262]. Further increases in PAR2 expression were noted
in monocytes, and the PAR2-agonist peptide upregulated
IL-6. In contrast, PAR2 expression was decreased after
treatments with antirheumatic drugs [263], further sup-
porting the role of PAR2 in rheumatic disease.
PAR modulators as targets for therapy
The complexity of PAR regulation is indicated by the
culmination of specific proteolytic cleavage modes (in-
activating or activating), protease inhibitors, and cofac-
tors, and with the effects of PAR glycosylation and
dimerization (Fig. 1). In this section we discuss classes of
agonists and antagonists that have been tested as PAR
modulators for use as therapeutic agents as summarized
in Fig. 6 and Tables 5, 6 and 7.
Peptide agonists and antagonists are short synthetic
peptides that mimick the PAR-tethered ligand that is lib-
erated by proteolytic cleavage, as described above. These
peptides either induce signal transduction or prevent
cleavage-dependent signaling following PAR rapid in-
ternalization, and some C- or N-terminal modifications
of soluble ligand sequences have resulted in increased
activation efficiency [18]. Peptidomimetic antagonists
are small protein-like chains that mimick the tethered li-
gands of PARs, and were recently used as PAR modula-
tors for the first time [264].Soon after PARs were
discovered, PAR1 blocking antibodies were reported
[265], and these blocked protease binding and or the
cleavage site of the receptor. Non-peptide small mole-
cules, such as the PAR1 antagonists vorapaxar [266] and
atopaxar [267], also interact with PARs, mainly via
ECL2.Only two classes of intracellular PAR antagonists
have been developed to date. Pepducins are cell pene-
trating palmitoylated peptides that were derived from
the intracellular loop of PAR, and these interfere with G
protein binding [268]. Parmodulins, in contrast, are
small molecules that bind PARs at the G protein binding
pocket of the C-tail to compete with Gαq subunits, but
not with other Gα subunits [269].
Examination of agonists and antagonists in vitro and in
preclinical studies (Tables 5, 6 and 7)
Clinical studies
Despite the importance of PARs in various pathophysio-
logical conditions, few PAR modulating tools have been
tested in clinical studies, and even fewer have been
established for treatment. Since the identification of
PAR1 as a platelet thrombin receptor, an abundance of
research has been conducted to identify PAR1 antago-
nists that can block platelet activation and prevent
thrombotic cardiovascular events. The first clinically ap-
proved PAR1 antagonist was the small-molecule antag-
onist vorapaxar [266]. Phase II clinical trials of this
agent showed reduced risks for myocardial infarction in
patients treated with vorapaxar in combination with
standard antiplatelet therapy. Moreover, the risks of
bleeding complications were not significantly increased
[270]. Subsequently, two large-scale phase III multicen-
ter, randomized, double-blind, placebo-controlled studies
of vorapaxar (ZONTIVITY, SCH530348) were per-
formed. In the Thrombin Receptor Antagonist in Sec-
ondary Prevention of Atherothrombotic Ischemic
Events–Thrombolysis in Myocardial Infarction 50 (TRA
2°P-TIMI 50; details at www.ClinicalTrials.gov;
NCT00526474) study, the rate of cardiovascular events
at the second efficacy endpoint were significantly re-
duced by vorapaxar in combination with standard anti-
platelet therapy [271]. Furthermore, in the Thrombin
Receptor Antagonist for Clinical Event Reduction in
Acute Coronary Syndrome (TRACER; details at www.
ClinicalTrials.gov; NCT00527943) study, vorapaxar re-
duced the hazard of first myocardial infarction of any
type in patients who were treated within 24 h of having
symptoms of a cardiovascular event. However, in the
TRACER study, vorapaxar failed to prevent secondary
ischemic events [272]. Because vorapaxar increased
bleeding complications in the clinical setting, the alter-
native PAR1 antagonist atopaxar (E5555) [267] was
tested in a phase II clinical trial called (Lessons From
Antagonizing the Cellular Effects of Thrombin-Acute
Fig. 6 PAR modulators. Pharmacological substances, such as 1)
peptides and peptidomimetics, 2) blocking antibodies, 3) small
molecules, 4) pepducins, and 5) parmodulins are used as therapeutic
agents that affect PAR activities
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Table 5 PAR1 signaling modulators
Class Agonist/
Antagonist
Name Receptor/Cell/
Tissue type
Cellular response
Peptide Agonist SFLLRN/−NH2 Human Induces platelet activation [6, 138, 265, 278, 279]
TFLLRN/−NH2 Human Induces platelet activation, enhances endothelial barrier permeability
[137, 138, 265]
NPNDKYEPF/
−NH2
Human Induces cytoprotective signaling [28, 187]
PRSFLLRN/−NH2 Human Induces platelet activation [86]
Human Induces ERK1/2 activation [280]
Antagonist YFLLRN Human Compets with thrombin and PAR1-AP and prevents platelet activation
[278, 279]
Peptidomimetic Antagonist RWJ-56110 Human Blunts thrombin and PAR1-AP effects on platelets and vascular endo-
thelial cells [264, 281, 282]
Human Blocks MMP-1 activaiton in SMCs [87]
RWJ-58259 Guinea pig Blocks thrombin and PAR1-AP platelet activation [215, 283]
Rat Blocks thrombin induced calcium release in AoSMC Inhibits intimal
thickening [111, 215, 264, 273]
Mouse Prevents destruction of intestinal barrier [62, 284]
Non-peptide small
molecule
Antagonist FR17113 Human Blocks PAR1-AP induced platelet activation [285, 286]
Human Inhibits thrombin and PAR1-AP induced ERK1/2 activation [287]
ER129614–06 Human Blocks thrombin and PAR1-AP induced platelet activation [288]
Guinea pig Shows antithrombotic effects [289]
F16357, F16618 Human Blocks PAR1-AP induced platelet activation [290]
Rat Shows antithrombotic effects [291]
SCH79797 Human Blocks thrombin and PAR1-AP induced calcium release and platelet ac-
tivation [292]
Human, Mouse Induces NETs formation and increases bacterial killing capacity [293]
SCH203009 Human Blocks thrombin and PAR1-AP induced platelet activation [292]
SCH530348
(vorapaxar)
Human, Monkey Blocks thrombin and PAR1-AP induced platelet activation [266]
E5555 (atopaxar) Human Blocks thrombin and PAR1-AP induced platelet activation and inhibits
thrombus formation [267]
Guinea pig Bleeding time not affected [267, 294]
Q94 Human Blocks thrombin induced calcium release [295]
Mouse Blocks thrombin induced ERK1/2 activation [296]
Pepducin Antagonist P1pal-12 Human Blocks thrombin induced platelet activation [268]
Human Blocks platelet activation [86]
Human Blocks MMP-1 induced endothelial damage [297]
Mouse Reduces lung vascular damage and sepsis lethality [297, 298]
P1-pal7
(PZ-128)
Human Blocks MMP-1 induced Akt signaling in cancer cells [150]
Human Blocks platelet activation [86]
Mouse Inhibits tumor growth [280]
Guinea pig Prevents from systemic platelet activation [86]
Parmodulin Antagonist ML161
(Parmodulin-2)
Human Blocks thrombin and PAR1-AP induced platelet activation [299]
Human Blocks thrombin induced inflammatory signaling on
endothelial cells [269]
Mouse Blocks thrombus formation [300]
Antibiotic Antagonist Doxycycline Human Inhibits thrombin induced cancer cell migration [301, 302]
Human Blocks MMP-1 cleavage [303]
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Table 5 PAR1 signaling modulators (Continued)
Class Agonist/
Antagonist
Name Receptor/Cell/
Tissue type
Cellular response
Antibody Antagonist ATAP-2
WEDE
Human Blocks thrombin cleavage of PAR1 and thrombin induced calcium
release [147]
Table 6 PAR2 signaling modulators
Class Agonist/
Antagonist
Name Receptor/Cell/Tissue
type
Cellular response
Peptide Agonist SLIGRL/−NH2 Human, Rat Induces calcium release [2, 8, 136, 139]
SLIGKV/−NH2 Human Induces calcium release [136]
2f-LIGRLO/
−NH2
Human, Rat Induces calcium release [140]
Antagonist FSLLRY-NH2 Human Blocks trypsin, not SLIGRL activation, reduces proinflammatory IL-8
and TNFα [82]
Rat Inhibits neuropathic pain [304]
LSIGRL-NH2 Human Blocks trypsin, not SLIGRL induced calcium release [305]
Peptidomimetic Antagonist K14585,
K12940
Human Reduces SLIGKV induced calcium release [306]
Human Inhibits SLIGRL induced NFkB activation [307]
C391a Human, Mouse Blocks calcium release and MAPK activation [308]
Non-peptide small
molecule
Agonist GB110 Human Induces calcium release [309]
AC-5541,
AC-264613
Human Induces calcium release [310]
Rat Induces edema and hyperalgesia [310]
Antagonist ENMD-1068 Human Blocks p.acnes induced calcium release and induction of IL-1a, IL-8
and TNFα [92]
Human Inhibited FVIIa induced cancer cell migration [311]
Mouse Reduces joint inflammation [260]
Mouse Blocks calcium release and reduces liver fibrosis [312]
GB83 Human Inhibits trypsin and PAR2-AP calcium release [313]
GB88 Human Blocks PAR2 induced calcium release [309]
Rat Reduces acute paw edema, inhibits PAR2-AP induced inflammation
[309, 314]
AZ8838
AZ3451
Human Blocks PAR2-AP induced calcium release and β-arrestin
recruitment [315]
Pepducin Antagonist P2pal-18S Human Blocks PAR2 induced calcium release [316]
Mouse Decreases risk for developing severe biliary pancreatitis [317]
P2pal-14GQ Human Blocks PAR2 induced calcium release [316]
Antibiotic Antagonist Tetracyclines
(Tetracycline,
Doxycycline,
Minocycline)
Human Inhibits SLIGRL induced IL-8 release [318]
Mouse Topical application of tetracycline decreases PAR2 induced skin
inflammation [319]
Rat Subantimicrobial doses of doxycycline inhibit PAR2 induced
inflammation [320]
Antibody SAM-11 Mouse Reduces joint inflammation [260]
Mouse Prevents allergic inflammation [124]
B5 Mouse Reduces joint inflammation [260]
Mouse Inhibits allergic airway inflammation [124]
MAB3949 Human Blocks trypsin induced PAR2 activation [315]
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Coronary Syndromes (LANCELOT-ACS; details at www.
ClinicalTrials.gov; NCT00548587) study [273]. Atopaxar
inhibited platelet aggregation in ACS patients in a
dose-dependent manner, and caused no side effects of
abnormal platelet activation, such as bleeding [274, 275].
Yet, patients receiving atopaxar had dose-dependent in-
creases in liver abnormalities [273].
To prevent the bleeding problems that arise from treat-
ments with PAR1 antagonists, a new class of PAR1 antag-
onist was designed, and the member pepducin PZ-128
(P1-pal7) was tested in a phase I trial [276]. This study
showed no reduction in platelet aggregation, but the plate-
let blocking effect of PZ-128 was reversible ex vivo in the
presence of saturating concentrations of the PAR1 agonist
peptide SFLLRN. Based on these promising findings, the
new PAR1 blocking agent PZ-128 was considered in the
coronary artery disease study Thrombin Receptor Inhibi-
tory Pepducin-Percutaneous Coronary Intervention
(TRIP-PCI). Data from this phase II trial are not yet avail-
able (details at www.ClinicalTrials.gov; NCT02561000).
As an alternative to PAR1 targeted antithrombotic drugs,
the PAR4 small-peptide antagonist BMS-986120 reduced
reversible thrombus formation ex vivo in a phase I trial
[277]. Consequently, this promising anticoagulant PAR4
antagonist is currently being compared with a standard
anticoagulant drug in a phase II study of stroke recurrence
(details at www.ClinicalTrials.gov; NCT02671461).
Conclusion
Since the identification of PARs in the 1990s, studies of
the complex mechanisms of PAR activation have been
abundant, and these have clarified the roles of PARs in
inflammatory disease. Various mammalian and
non-mammalian proteases have also been recognized as
PAR-mediated regulators of physiological and patho-
physiological processes. Despite the development of vari-
ous PAR modulators, few have been approved for
therapeutic use. Obstacles to this therapeutic strategy in-
clude species differences in PAR expression and limited
bioavailability of modulators in vivo and in clinical stud-
ies. Further research is needed to identify specific and ef-
ficient anti-inflammatory PAR modulators.
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Table 7 PAR4 signaling modulators
Class Agonist/ Antagonist Name Receptor/Cell/Tissue type Cellular response
Peptide Agonist GYPGQV/−NH2 Human, Rat Induces platelet activation [144]
GYPGKF/−NH2 Human, Rat Induces platelet activation [144]
AYPGKF/−NH2 Human, Mouse Induces platelet activation [145]
Peptidomimetic Antagonist tc-YGPKF Rat Blocks thrombin and PAR4-AP induced
platelets aggregation [321]
Non-peptide small molecule Antagonist YD-3 Human Blocks thrombin induced platelet
activation [282, 322–325]
Mouse, Rat, Rabbit Blocks thrombin and PAR4-AP induced
platelets activation [323–325]
ML-354 Human Blocks PAR4-AP induced platelet
activation [326–328]
BMS-986120 Human Blocks PAR4-AP induced calcium
release and platelet activation [329]
Human Blocks thrombus formation at
high shear stress [277]
Monkey Blocks platelet activation [329]
Pepducin Antagonist P4pal-10 Human, Mouse Blocks thrombin and PAR4-AP
induced platelet activation [268]
Rat Blocks thrombin and PAR4-AP induced
platelets activation [330]
P4pal-i1 Human Blocks PAR4 induced platelets activation [150]
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